Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia

BCR-ABL1 kinase domain mutations are a major mechanism of tyrosine kinase inhibitor (TKI) resistance in patients with chronic myeloid leukemia (CML). These mutations interfere the binding of TKIs to the binding site [1 –3]. To date, various studies have shown that some of these mutations are strongly related to clinical resistance [2–5], and the sensitivity to different TKIs is dependent on the type of mutation [6–10]. Patients with multiple mutations have poorer prognosis than patients with a single mutatio n [11,12].
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research